Outcomes and Cosmesis With Whole Breast Irradiation and Boost

This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.

Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Histologically confirmed early stage (stage T1-T2) invasive carcinoma of the breast or DCIS * Breast conserving surgery with negative margins and negative nodes (surgical axillary staging not mandatory), stage N0 or Nx * Treatment plan should include breast conserving surgery and adjuvant whole breast irradiation (WBI) therapy delivered with 3D-CRT or IMRT techniques * Treatment plan includes breast tumor bed boost * Willingness to comply with all study procedures and be available for the duration of the study Exclusion Criteria: * Mastectomy of ipsilateral breast * Lack of histologic diagnosis * Histologic involvement of the axillary or regional nodes or metastatic disease * Accelerated partial breast irradiation treatment plan * Previous history of non-breast malignancy diagnosed in the past 5 years except for basal or squamous cell cancer of the skin * Previous history of chest radiation therapy * Previous history of ipsilateral breast cancer * Concurrent cytotoxic chemotherapy * Active connective tissue disease including scleroderma * Inability or unwillingness to return for required follow up visit